top banner imagetop banner mobile image

Press Releases

Date Title
12/28/17
Summary ToggleTherapeuticsMD Announces Submission of New Drug Application for TX-001HR
12/19/17
Summary ToggleTherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for TX-004HR
11/29/17
Summary ToggleTherapeuticsMD Announces Resubmission of New Drug Application for TX-004HR
11/07/17
Summary ToggleTherapeuticsMD to Present at Two Upcoming Investor Conferences
11/06/17
Summary ToggleTherapeuticsMD Announces Third Quarter 2017 Financial Results
11/06/17
Summary ToggleTherapeuticsMD Announces Plan to Resubmit the New Drug Application for TX-004HR
11/03/17
Summary ToggleTherapeuticsMD to Host TX-004HR Regulatory Update and Third Quarter Financial Results Conference Call and Webcast on November 6
10/05/17
Summary ToggleTherapeuticsMD Announces Multiple Presentations Related to TX-004HR and TX-001HR at NAMS 2017
09/28/17
Summary ToggleTherapeuticsMD Announces Closing of Common Stock Offering
09/25/17
Summary ToggleTherapeuticsMD Announces Pricing of Common Stock Offering
09/25/17
Summary ToggleTherapeuticsMD Announces Public Offering of 12.4 Million Shares of Common Stock
09/25/17
Summary ToggleTherapeuticsMD Announces Move to Nasdaq Global Select Market
09/14/17
Summary ToggleTherapeuticsMD Announces Submission of Additional Endometrial Safety Information to the New Drug Application for TX-004HR
09/06/17
Summary ToggleTherapeuticsMD to Present at Two Upcoming Investor Conferences
08/16/17
Summary ToggleTherapeuticsMD Announces Publication of Manuscript on the Women’s Health Initiative Observational Study of Vaginal Estrogen Use in Postmenopausal Women
08/10/17
Summary ToggleTherapeuticsMD Provides TX-004HR Regulatory Update
08/03/17
Summary ToggleTherapeuticsMD Announces Second Quarter 2017 Financial Results
07/20/17
Summary ToggleTherapeuticsMD to Host Second Quarter Financial Results Conference Call and Webcast on August 3
07/17/17
Summary ToggleTherapeuticsMD Provides TX-004HR Regulatory Update
05/23/17
Summary ToggleTherapeuticsMD Announces Presentation at Jefferies 2017 Healthcare Conference on June 8
05/10/17
Summary ToggleTherapeuticsMD Announces Presentation at Bank of America Merrill Lynch 2017 Healthcare Conference on May 16
05/08/17
Summary ToggleTherapeuticsMD Receives Complete Response Letter from FDA for TX-004HR New Drug Application
05/02/17
Summary ToggleTherapeuticsMD to Host TX-004HR Regulatory Update Conference Call and Webcast on May 8
05/02/17
Summary ToggleTherapeuticsMD Announces First Quarter 2017 Financial Results
04/19/17
Summary ToggleTherapeuticsMD Provides Additional Information on TX-004HR Regulatory Update
04/10/17
Summary ToggleTherapeuticsMD Provides TX-004HR Regulatory Update
04/03/17
Summary ToggleTherapeuticsMD Presents Positive Phase 3 Data in Two Presentations for TX-001HR at ENDO 2017
03/16/17
Summary ToggleTherapeuticsMD Announces Presentation at the Oppenheimer 27th Annual Healthcare Conference on March 22
03/03/17
Summary ToggleTherapeuticsMD Announces Presentation at Cowen and Company 37th Annual Healthcare Conference on March 7
02/23/17
Summary ToggleTherapeuticsMD Announces Fourth Quarter and Full-Year 2016 Financial Results
02/15/17
Summary ToggleTherapeuticsMD Announces Webcast of Investor Day on March 1
02/09/17
Summary ToggleTherapeuticsMD to Host Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast on February 23
01/19/17
Summary ToggleTherapeuticsMD Announces Investor Day on March 1
01/11/17
Summary ToggleTherapeuticsMD Announces Publication of Two Manuscripts on the Rejoice Trial for TX-004HR in Leading Peer-Reviewed Medical Journal
01/03/17
Summary ToggleTherapeuticsMD to Present at 35th Annual J.P. Morgan Healthcare Conference on January 11